|Print Page Close Window|
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The company is focused on developing and commercializing its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for Renal Cell Carcinoma and other cancers. AVEO is leveraging multiple partnerships to develop and commercialize tivozanib in non-oncologic indications worldwide and oncology indications outside of North America, as well as to progress its pipeline of novel therapeutic candidates in cancer and cachexia (wasting syndrome).
04/20/17AVEO Announces Presentations at the 2017 ASCO Annual MeetingRead More
04/13/17AVEO Announces Submission of Response to Tivozanib Marketing Authorization Application Day 180 List of Outstanding IssuesRead More
04/03/17AVEO Announces Milestone Payment from CANbridge for AV-203Read More
02/13/17 8:30 a.m. ET AVEO Oncology at the 19th Annual BIO CEO & Investor Conference
Corporate PresentationAVEO Oncology Corporate Presentation